A Randomized, Double-Blind, Parallel-Controlled Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of SCT510 to Bevacizumab (Avastin) in Healthy Chinese Males

Overview

Journal Drugs R D

Specialty Pharmacology

Date 2023 May 29

PMID 37247166

Authors

Jing Wu

Guolan Wu

Liangzhi Xie

Duo Lv

Chang Xu

Huili Zhou

Lihua Wu

Jingjing Zhang

Jianzhong Shentu

Affiliations

Soon will be listed here.

Abstract

Background: SCT510 is a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), which is intended as a candidate biosimilar of bevacizumab that is approved for various metastatic cancers.Please confirm change in wording to match definition for VEGF belowYes.

Objective: This study aimed to compare the pharmacokinetics profiles, safety, and immunogenicity of SCT510 to bevacizumab (Avastin) in healthy Chinese males.

Methods: This was a single-center, double-blind, parallel-group phase I study. A total of 84 participants were randomly assigned (1:1) to receive a single 3 mg/kg infusion of either SCT510 or bevacizumab and followed up for 99 days. Primary endpoints were area under the serum concentration-time curve from time 0 extrapolated to infinity (AUC), area under the serum concentration-time curve from time 0 to last quantifiable concentration (AUC), and the maximum observed concentration (C). Secondary endpoints included safety and immunogenicity.Kindly check and confirm the edit made in the article title.Yes.

Results: A total of 82 subjects completed the study. Geometric means ratios (GMR) for AUC, AUC, and C were 0.88, 0.89, and 0.97, respectively, for SCT510 versus bevacizumab (USA). The 90% confidence intervals for GMRs of AUC, AUC, and C were all within the prespecified criteria (80-125%). No adverse events (AEs) led to study termination, and no serious adverse events (SAEs) were reported. None of the anti-drug antibodies (ADAs) identified were found to be neutralizing antibodies (NAbs), and only one subject from the SCT510 group tested positive for the ADA at the day 99 visit.

Conclusion: This study demonstrated that the pharmacokinetics, safety, and immunogenicity of SCT510 were equivalent to bevacizumab (Avastin). As a proposed biosimilar drug to bevacizumab, SCT510 was well tolerated in healthy Chinese males.

Clinical Trials Registration: NCT05113511.

Citing Articles

Evaluating biosimilars: safety, efficacy, and regulatory considerations in clinical studies.

Liu Y, Wang Y, Wang M, Zhai S, Hou C, Sun F Int J Clin Pharm. 2024; 47(1):232-236.

PMID: 39527168 PMC: 11748480. DOI: 10.1007/s11096-024-01825-8.

The Trend of the Treatment of Advanced Hepatocellular Carcinoma: Combination of Immunotherapy and Targeted Therapy.

Dong H, Zhang Z, Ni M, Xu X, Luo Y, Wang Y Curr Treat Options Oncol. 2024; 25(10):1239-1256.

PMID: 39259476 PMC: 11485193. DOI: 10.1007/s11864-024-01246-9.

Efficacy and Safety of Biosimilar SCT510 Compared with Bevacizumab for the First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study.

Cheng Y, Pan Z, Wu L, Zhu B, Yu Y, Zang K Adv Ther. 2024; 41(11):4032-4048.

PMID: 39230871 DOI: 10.1007/s12325-024-02965-z.

References

Eto T, Karasuyama Y, Gonzalez V, Del Campo Garcia A . A randomized, single-dose, pharmacokinetic equivalence study comparing MB02 (proposed biosimilar) and reference bevacizumab in healthy Japanese male volunteers. Cancer Chemother Pharmacol. 2021; 88(4):713-722. PMC: 8367884. DOI: 10.1007/s00280-021-04324-z. View

Zhou C, Wu Y, Chen G, Liu X, Zhu Y, Lu S . BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2015; 33(19):2197-204. DOI: 10.1200/JCO.2014.59.4424. View

Shin D, Lee Y, Choi J, Lee D, Park M, Petkova M . A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers. Cancer Chemother Pharmacol. 2020; 86(4):567-575. PMC: 7515939. DOI: 10.1007/s00280-020-04144-7. View

Gordon M, Margolin K, Talpaz M, Sledge Jr G, Holmgren E, Benjamin R . Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001; 19(3):843-50. DOI: 10.1200/JCO.2001.19.3.843. View

Oguntade A, Al-Amodi F, Alrumayh A, Alobaida M, Bwalya M . Anti-angiogenesis in cancer therapeutics: the magic bullet. J Egypt Natl Canc Inst. 2021; 33(1):15. DOI: 10.1186/s43046-021-00072-6. View

Pfisterer J, Shannon C, Baumann K, Rau J, Harter P, Joly F . Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncol. 2020; 21(5):699-709. DOI: 10.1016/S1470-2045(20)30142-X. View

Ferrara N, Gerber H, LeCouter J . The biology of VEGF and its receptors. Nat Med. 2003; 9(6):669-76. DOI: 10.1038/nm0603-669. View

Dhillon S . Bevacizumab combination therapy: for the first-line treatment of advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. Drugs. 2012; 72(7):917-30. DOI: 10.2165/11208940-000000000-00000. View

Mcdermott D, Huseni M, Atkins M, Motzer R, Rini B, Escudier B . Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018; 24(6):749-757. PMC: 6721896. DOI: 10.1038/s41591-018-0053-3. View

10.

Shih T, Lindley C . Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther. 2007; 28(11):1779-802. DOI: 10.1016/j.clinthera.2006.11.015. View

11.

Moorkens E, Vulto A, Huys I . An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?. MAbs. 2020; 12(1):1743517. PMC: 7188399. DOI: 10.1080/19420862.2020.1743517. View

12.

Zirlik K, Duyster J . Anti-Angiogenics: Current Situation and Future Perspectives. Oncol Res Treat. 2018; 41(4):166-171. DOI: 10.1159/000488087. View

13.

Stroyakovskiy D, Fadeeva N, Matrosova M, Shelepen K, Adamchuk G, Roy B . Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab. BMC Cancer. 2022; 22(1):129. PMC: 8808992. DOI: 10.1186/s12885-022-09243-7. View

14.

Zhou R, Yang J, Liu Y, Zhang Q, Lu C, Tang K . A randomized, double-blind, parallel-group phase I study comparing the pharmacokinetics, safety, and immunogenicity of LY01008, a candidate bevacizumab biosimilar, with its reference product Avastin® in healthy Chinese male subjects. Expert Opin Biol Ther. 2021; 22(2):263-269. DOI: 10.1080/14712598.2022.2019703. View

15.

Huang K, Que L, Ding Y, Chu N, Qian Z, Shi Y . A Randomized, Double-Blind, Single-Dose Study Comparing the Biosimilarity of HOT-1010 With Bevacizumab (Avastin®) in Chinese Healthy Male Subjects. Front Pharmacol. 2021; 12:694375. PMC: 8245695. DOI: 10.3389/fphar.2021.694375. View

16.

Wynne C, Schwabe C, Batra S, Lopez-Lazaro L, Kankanwadi S . A comparative pharmacokinetic study of DRL_BZ, a candidate biosimilar of bevacizumab, with Avastin (EU and US) in healthy male subjects. Br J Clin Pharmacol. 2018; 84(10):2352-2364. PMC: 6138499. DOI: 10.1111/bcp.13691. View

17.

Ghiaseddin A, Reardon D, Massey W, Mannerino A, Lipp E, Herndon 2nd J . Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma. Oncologist. 2017; 23(2):157-e21. PMC: 5813746. DOI: 10.1634/theoncologist.2017-0501. View

18.

Hubel K, Kron F, Lux M . Biosimilars in oncology: Effects on economy and therapeutic innovations. Eur J Cancer. 2020; 139:10-19. DOI: 10.1016/j.ejca.2020.07.037. View

19.

Falk A, Barriere J, Francois E, Follana P . Bevacizumab: A dose review. Crit Rev Oncol Hematol. 2015; 94(3):311-22. DOI: 10.1016/j.critrevonc.2015.01.012. View

20.

Mulcahy A, Hlavka J, Case S . Biosimilar Cost Savings in the United States: Initial Experience and Future Potential. Rand Health Q. 2018; 7(4):3. PMC: 6075809. View